Venetoclax combination therapy in relapsed ALL

Venetoclax combination therapy in relapsed ALL

VJHemOnc

1 year
72 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
There is an unmet need for treatment options for acute lymphoblastic leukemia (ALL) patients who have relapsed on multiple prior therapies. Thomas Alexander, MD, PhD, of the University of North Carolina School of Medicine, Chapel Hill, NC, presented data from his trial (NCT03181126) exploring the efficacy of the BCL2 inhibitors venetoclax and navitoclax with chemotherapy in these patient groups at the 23rd Congress of the European Hematology Association (EHA) 2018, in Stockholm, Sweden. In this video, he discusses certain ALL subgroups which respond better to BCL2 inhibition, how to extrapolate pediatric safety data from adult data, and the rationale behind developing combination therapies like this one when immunotherapy is coming to the forefront of ALL research and treatment.
Up Next Autoplay
National Brain Tumor Society to Provide Funding for ONC201 Trial in EGFR-Independent High-Grade Gliomas
National Brain Tumor Society to Provide Funding for ONC201 Trial in EGFR-Independent High-Grade Gliomas
Category: Acute Lymphoblastic Leukemia
2 Views
alexvarney 13 hours
Statement on New ASH Clinical Practice Guidelines on Sickle Cell Disease-Related Transfusion Support
Statement on New ASH Clinical Practice Guidelines on Sickle Cell Disease-Related Transfusion Support
Category: News
1 Views
Cancer-News 14 hours
GRACE Supportive Care Series:   Chemobrain with Guest, Lysa Buonnano
GRACE Supportive Care Series: Chemobrain with Guest, Lysa Buonnano
Category: Supportive Care
1 Views
cancergrace 3 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: General
3 Views
Cancer-News 4 days
TOURMALINE-MM4: What's Next in Research?
TOURMALINE-MM4: What's Next in Research?
Category: Multiple Myeloma
2 Views
Cancer-News 4 days
TOURMALINE-MM4: Are There Safety Concerns?
TOURMALINE-MM4: Are There Safety Concerns?
Category: Multiple Myeloma
2 Views
Cancer-News 4 days
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Category: News
0 Views
ash 4 days
What should clinicians know about patients with the H3 K27M mutation?
What should clinicians know about patients with the H3 K27M mutation?
Category: Brain Cancer
3 Views
Massachusetts General Hospital 4 days
TOURMALINE-MM4: Regulatory Pathway
TOURMALINE-MM4: Regulatory Pathway
Category: Multiple Myeloma
2 Views
Cancer-News 4 days
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
Category: Brain Cancer
1 Views
Massachusetts General Hospital 4 days